Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
Genital Neoplasms, Female
DRUG: BIBF 1120|DRUG: Paclitaxel|DRUG: Carboplatin
Maximum tolerated dose (MTD) of BIBF 1120, up to 126 days|Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120, up to 9 months
Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients, up to 9 months|Cancer antigen 125 (CA-125) response, Day 1 of each treatment period|Time to tumour progression (time from treatment start to the time of documented tumour progression), up to 9 months
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel